GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alpa Laboratories Ltd (NSE:ALPA) » Definitions » EV-to-EBITDA

Alpa Laboratories (NSE:ALPA) EV-to-EBITDA : 3.45 (As of May. 13, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Alpa Laboratories EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alpa Laboratories's enterprise value is ₹826 Mil. Alpa Laboratories's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₹240 Mil. Therefore, Alpa Laboratories's EV-to-EBITDA for today is 3.45.

The historical rank and industry rank for Alpa Laboratories's EV-to-EBITDA or its related term are showing as below:

NSE:ALPA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.98   Med: 5.18   Max: 52.65
Current: 3.45

During the past 13 years, the highest EV-to-EBITDA of Alpa Laboratories was 52.65. The lowest was -3.98. And the median was 5.18.

NSE:ALPA's EV-to-EBITDA is ranked better than
94.03% of 704 companies
in the Drug Manufacturers industry
Industry Median: 14.705 vs NSE:ALPA: 3.45

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-13), Alpa Laboratories's stock price is ₹90.05. Alpa Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹8.540. Therefore, Alpa Laboratories's PE Ratio for today is 10.54.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Alpa Laboratories EV-to-EBITDA Historical Data

The historical data trend for Alpa Laboratories's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpa Laboratories EV-to-EBITDA Chart

Alpa Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.30 -2.30 2.80 3.84 2.00

Alpa Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.62 2.00 8.50 2.03 9.08

Competitive Comparison of Alpa Laboratories's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Alpa Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpa Laboratories's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alpa Laboratories's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Alpa Laboratories's EV-to-EBITDA falls into.



Alpa Laboratories EV-to-EBITDA Calculation

Alpa Laboratories's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=826.424/239.524
=3.45

Alpa Laboratories's current Enterprise Value is ₹826 Mil.
Alpa Laboratories's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹240 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alpa Laboratories  (NSE:ALPA) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Alpa Laboratories's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=90.05/8.540
=10.54

Alpa Laboratories's share price for today is ₹90.05.
Alpa Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8.540.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Alpa Laboratories EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Alpa Laboratories's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpa Laboratories (NSE:ALPA) Business Description

Traded in Other Exchanges
Address
33/2, A.B. Road, Pigdamber, Rau, Indore, MP, IND, 453446
Alpa Laboratories Ltd is an India-based pharmaceutical company. It operates in the business segment of Drugs and Chemicals. The company manufactures and markets pharmaceuticals and related products. It sells products like liquid injection, dry powder injection, tablets, capsules, and ointments.